Halozyme Therapeutics, Inc. (NASDAQ:HALO) had a loss and beat Wall Street’s expectations, AND beat the revenue expectation. The revenue beat is a positive sign to shareholders seeking high growth out of the company. Shares are up 0.85%.
Halozyme Therapeutics, Inc. Earnings Cheat Sheet
Results: Adjusted Earnings Per Share increased to $-0.04 in the quarter versus EPS of $-0.18 in the year-earlier quarter.
Revenue: Rose 804.56% to $21.8 million from the year-earlier quarter.
Actual vs. Wall St. Expectations: Halozyme Therapeutics, Inc. reported adjusted EPS loss of $0.04 per share. By that measure, the company beat the mean analyst estimate of $-0.15. It beat the average revenue estimate of $7.32 million.
Quoting Management: “2012 was another productive year marked by key partner regulatory filings in Europe, as well as our establishment of a new collaboration with Pfizer,” said Gregory I. Frost, Ph.D., President and Chief Executive Officer, Halozyme. “These advancements, coupled with the continued progress of our own pipeline products, leave Halozyme well-positioned for continued growth in 2013.”
Key Stats (on next page)…